SimpliDerm is a pre-hydrated human acellular dermal matrix.
Aziyo Biologics, Inc. and Sientra, Inc. are joining forces to expand the distribution of Aziyo’s SimpliDerm product line.
Under the agreement terms, Aziyo will grant Sientra certain non-exclusive rights in the United States to market, sell, and distribute SimpliDerm for select use in reconstruction surgery.
SimpliDerm is a pre-hydrated human acellular dermal matrix (hADM) that uses a proprietary process to preserve key growth factors of native dermis that support faster integration and more rapid revascularization while demonstrating a lower risk of inflammatory response. Due to this unique process, SimpliDerm has been able to provide a pliable, conforming matrix in a ready-to-use format and achieve a sterility assurance level (SAL) of 10-6.
SimpliDerm is to be used for the repair or replacement of damaged or insufficient integumental tissue or for other homologous uses of human integument.
